Cargando…
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327738/ https://www.ncbi.nlm.nih.gov/pubmed/33657786 http://dx.doi.org/10.3324/haematol.2020.261842 |
| _version_ | 1783732157909303296 |
|---|---|
| author | Hulin, Cyrille Offner, Fritz Moreau, Philippe Roussel, Murielle Belhadj, Karim Benboubker, Lotfi Caillot, Denis Facon, Thierry Garderet, Laurent Kuhnowski, Frédérique Stoppa, Anne-Marie Kolb, Brigitte Tiab, Mourad Jie, Kon-Siong Westerman, Matthijs Lambert, Jérôme Pei, Lixia Vanquickelberghe, Veronique de Boer, Carla Vermeulen, Jessica Kampfenkel, Tobias Sonneveld, Pieter van de Donk, Niels W.C.J. |
| author_facet | Hulin, Cyrille Offner, Fritz Moreau, Philippe Roussel, Murielle Belhadj, Karim Benboubker, Lotfi Caillot, Denis Facon, Thierry Garderet, Laurent Kuhnowski, Frédérique Stoppa, Anne-Marie Kolb, Brigitte Tiab, Mourad Jie, Kon-Siong Westerman, Matthijs Lambert, Jérôme Pei, Lixia Vanquickelberghe, Veronique de Boer, Carla Vermeulen, Jessica Kampfenkel, Tobias Sonneveld, Pieter van de Donk, Niels W.C.J. |
| author_sort | Hulin, Cyrille |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8327738 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83277382021-08-11 Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study Hulin, Cyrille Offner, Fritz Moreau, Philippe Roussel, Murielle Belhadj, Karim Benboubker, Lotfi Caillot, Denis Facon, Thierry Garderet, Laurent Kuhnowski, Frédérique Stoppa, Anne-Marie Kolb, Brigitte Tiab, Mourad Jie, Kon-Siong Westerman, Matthijs Lambert, Jérôme Pei, Lixia Vanquickelberghe, Veronique de Boer, Carla Vermeulen, Jessica Kampfenkel, Tobias Sonneveld, Pieter van de Donk, Niels W.C.J. Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-03-04 /pmc/articles/PMC8327738/ /pubmed/33657786 http://dx.doi.org/10.3324/haematol.2020.261842 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Hulin, Cyrille Offner, Fritz Moreau, Philippe Roussel, Murielle Belhadj, Karim Benboubker, Lotfi Caillot, Denis Facon, Thierry Garderet, Laurent Kuhnowski, Frédérique Stoppa, Anne-Marie Kolb, Brigitte Tiab, Mourad Jie, Kon-Siong Westerman, Matthijs Lambert, Jérôme Pei, Lixia Vanquickelberghe, Veronique de Boer, Carla Vermeulen, Jessica Kampfenkel, Tobias Sonneveld, Pieter van de Donk, Niels W.C.J. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title_full | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title_fullStr | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title_full_unstemmed | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title_short | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study |
| title_sort | stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase iii cassiopeia study |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327738/ https://www.ncbi.nlm.nih.gov/pubmed/33657786 http://dx.doi.org/10.3324/haematol.2020.261842 |
| work_keys_str_mv | AT hulincyrille stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT offnerfritz stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT moreauphilippe stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT rousselmurielle stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT belhadjkarim stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT benboubkerlotfi stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT caillotdenis stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT faconthierry stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT garderetlaurent stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT kuhnowskifrederique stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT stoppaannemarie stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT kolbbrigitte stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT tiabmourad stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT jiekonsiong stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT westermanmatthijs stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT lambertjerome stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT peilixia stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT vanquickelbergheveronique stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT deboercarla stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT vermeulenjessica stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT kampfenkeltobias stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT sonneveldpieter stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy AT vandedonknielswcj stemcellyieldandtransplantationintransplanteligiblenewlydiagnosedmultiplemyelomapatientsreceivingdaratumumabplusbortezomibthalidomidedexamethasoneinthephaseiiicassiopeiastudy |